Turcios MEN, Ortiz DCR

Language: Spanish
References: 21
Page: 126-130
PDF size: 740.10 Kb.

ABSTRACT

Leishmaniasis is a zoonosis with worldwide distribution, endemic in Central and South America included in neglected diseases. It is caused by protozoa of the genus Leishmaniatransmitted to humans through the bite of sandfly insects of the genus Lutzomyia. The evolution of the disease depends on the immune response and the species of the parasite. Cutaneous leishmaniasis is the most frequent clinical form, mainly affecting exposed areas of the skin. Its usual clinical presentation is an ulcer with slightly elevated edges, indurated, not painful and covered by serous or seropurulent secretion. It is easily diagnosed in endemic areas, but its unusual forms are difficult to diagnose and can lead to inadequate treatment. Meglumine antimoniate is the medication of first choice, however it is characterized by adverse effects and serious toxic reactions, as well as the reactivation of varicella zoster virus. This article describes the case of a patient with cutaneous leishmaniasis and herpes zoster simultaneously, without association with meglumine antimoniate, who presented moderate adverse effects during the twenty days of treatment.

REFERENCES

1. Andrade-Narvaez FJ, Loria-Cervera EN, Sosa-Bibiano EI, van Wynsberghe NR. Asymptomatic infection with American cutaneous leishmaniasis. Memorias do Instituto Oswaldo Cruz. 2016 October; 111(10).

2. Espinoza-Morales D, Lucchetti Rodríguez A, Silva-Caso W, Suarez-Ognio L, Pons MJ, Del Valle Mendoza J. An atypical case of disseminated cutaneous leishmaniasis due to Leishmania peruviana in the valleys of Ancash-Peru. Asian Pacific journal of tropical medicine. 2017 November ; 10(11).

3. Vries HJC, Reedijk SH, Schallig HDFH. Cutaneous Leishmaniasis: Recent Developments in Diagnosis and Management. American Journal of Clinical Dermatology. 2015 February; 16(2).

4. Olliaro P, Grogl M, Boni M, Carvalho EM, Chebli H, et al.. Harmonized clinical trial methodologies for localized cutaneous leishmaniasis and potential for extensive network with capacities for clinical evaluation. PLOS Neglected Tropical Diseases. 2018 January; 10(11).

5. Ferreira de Souza RA, Andreoli RV, Toshie Kayano M, Lima Carvalho A. American cutaneous leishmaniasis cases in the metropolitan region of Manaus, Brazil: Association with climate variables over time. Geospatial health. 2015 April; 10(1).

6. Matute N, Espinoza C, Alger J, Padgett D, López E, Zúniga C. Caracterización Clínico epidemiológica de pacientes con leishmaniasis atendidos en el Hospital Escuela. Revista Medica Hondureña. 2009 Enero; 77(1).

7. Gobierno de la Republica de Honduras Secretaria de Salud. Manual para el Abordaje Integral de Las Leishmaniasis en Honduras. 12016th ed. 2016 UdVdlSyLS, editor. Tegucigalpa, M.D.C.: Línea Creativa; 2016.

8. Ponce Barahona OA, Caballero Castro HR. Leishmaniasis cutánea. Acta Pediátrica Hondureña. 2015 Abril 2014 a Marzo 2015; 5(1 y 2).

9. Reveiz ANS, Maia-Elkhoury ANS, Nicholls RS, Romero GAS, Yadon ZE. Interventions for American Cutaneous and Mucocutaneous Leishmaniasis: A Systematic Review Update. PLOS ONE (PLOS ONE). 2013 April; 10(5).

10. Garcia Bustos MF, Barrio A, Parodi C, Beckar J, Moreno S, Basombrio MA. Miltefosina versus antimoniato de meglumina en el tratamiento de la leishmaniasis mucosa. Medicina Buenos Aires. 2014 Octubre; 74(5).

11. Mitropoulos P, Konidas P, Durkin-Konidas M. New World cutaneous leishmaniasis: updated review of current and future diagnosis and treatment. Journal of the American Academy of Dermatology. 2010 March; 63(2).

12. Oliveira LF, Schubach AO, Martins MM, Passos SL, Oliviera RV, Marzochi MC, et al. Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. Acta tropica. 2011 March; 118(2).

13. Romero GAS, Flores M RMdM, Noronha EF, Macedo VdO. High frequency of skin reactions in patients with leishmaniasis treated with meglumine antimoniate contaminated with heavy metals: a comparative approach using historical controls. Memorias do Instituto Oswaldo Cruz. 2003 April; 98(1).

14. Arboleda M, Jaramillo L, Ortiz D, Diaz A. Leishmaniasis cutánea y herpes zoster. Revista Chilena de Infectología. 2013 Octubre; 30(6).

15. Ghorbani M, Farhoudi R. Leishmaniasis in humans: drug or vaccine therapy? Drug Design, Development and Therapy. 2018 January; 12: p. 25-40.

16. Zaghi D, Panosian C, Gutierrez MA, Gregson A, Taylor E, Ochoa MT. New World cutaneous leishmaniasis:current challenges in diagnosis and parenteral treatment. Journal of the American Academy of Dermatology. 2011 March; 64(3).

17. Librada Porriño Bustamante M, Sánchez López J, Dulanto Campos C, Naranjo Sintes R, Antonia Fernández Pugnaire M. Dermatoscopic signs in cutaneous leishmaniasis. Anais Brasileiros de Dermatologia. 2017 December; 92(6).

18. Maia-Elkhoury ANS, E Yadon Z, Idali Saboya Diaz M, de Fatima de Araujo Lucena F, Gerardo Castellanos L, J Sanchez-Vasquez M. Exploring Spatial and Temporal Distribution of Cutaneous Leishmaniasis in the Americas, 2001-2011. PLOS neglected tropical diseases. 2016 November; 10(11).

19. Chongo Alfaro ML, García Echegoyen R. Leishmaniasis y transfusión. Artículo de revisión. Asociacion Mexicana de Medicina Transfusional, A.C. 2010 Mayo - Agosto; 3(1).

20. Melendez-Oviedo V, Gonzalez-Matute M, Sierra M, Alger J, Zúniga C, Lopez-Lutz E. Estudio comparativo entre antimoniato de meglumina. Revista Medica de los Post Grados de Medicina. 2006 Mayo-Agosto; 9(2).

21. Barros AB, Rodrigues AM, Batista MP, Munhoz Junior S, Hueb M, Fontes CJ. Varicella zoster virus reactivation during or immediately following treatment of tegumentary leishmaniasis with antimony compounds. Memorias do Instituto Oswaldo Cruz. 2014 June; 109(4).